Skip to content
Article Rich – Lifestyle
Author:
Tongrui Biomedicine (Shanghai) Co., LTD
C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)
April 28, 2026
C-Ray Therapeutics and SHINE Technologies Enter Strategic Partnership for Exclusive Distribution of No-Carrier-Added Lu-177 in Mainland China
March 26, 2026
C-Ray Therapeutics Achieves AAALAC International Full Accreditation, Reinforcing Commitment to Excellence in Preclinical Research
March 4, 2026